sCD163 and sMR in Wilsons Disease - Associations With Disease Severity and Fibrosis

University of Aarhus

Status: Completed

Conditions: Wilsons Disease

Treatments: Procedure: Ultrasound; Procedure: Functional hepatic nitrogen clearance; Drug: Galactose; Procedure: Fibroscan; Procedure: Liver biopsy

Study type: Interventional

Funder types: Other

Identifiers

NCT02702765

Wilson sCD163

Details and patient eligibility

About

The aim is to investigate macrophage activation markers and correlations to liver fibrosis in patients with Wilsons Disease. Researchers wish to investigate associations to neurologic and metabolic liver function. Researchers will assess this by comparing blood samples with fibrosis and liver function analyses. This study provides new insight into macrophages and their involvement in Wilsons Disease.

Enrollment: 33 patients

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• diagnosed with Wilsons disease

Exclusion criteria

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

33 participants in 1 patient group

Wilsons disease

Experimental group

Description:

All patients will receive all interventions (galactose elimination capacity test , ultrasound, fibroscan, continuous reaction time test and functional hepatic nitrogen clearance ), except liver biopsy.

Treatment:

Procedure: Liver biopsy

Procedure: Fibroscan

Procedure: Ultrasound

Drug: Galactose

Procedure: Functional hepatic nitrogen clearance